Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

NCT01770171 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Stage III-IV or Recurrent Endometrial Cancer

Interventions

DRUG: Bevacizumab
DRUG: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles

Sponsor

Catholic University of the Sacred Heart